MCL1 and triple-negative breast carcinoma: MCL1 is also frequently upregulated in breast cancer48, especially in drug-resistant triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy, with MCL1 (54%) and MYC (35%) gene coamplifications49.